Government-Owned Inventions; Availability for Licensing, 44667-44668 [05-15348]
Download as PDF
<![CDATA[
Federal Register / Vol. 70, No. 148 / Wednesday, August 3, 2005 / Notices
when the bacteriophage infects a
bacterial cell. These bacteriophages are
separately contacted with a sample
contaminated by a bacterium.
Expression of the reporter is then
detected, indicating which
bacteriophage has infected a bacterial
cell and is thus a potential therapeutic
phage against the particular bacteria.
Also claimed in the application are kits
allowing for the rapid identification of
potentially therapeutic bacteriophages.
Bacteriophage Having Multiple Host
Range
Carl Merril (NIMH), Sankar Adhya
(NCI), Dean Scholl (NIMH).
U.S. Provisional Application No. 60/
220,987 filed 25 Jul 2000 (HHS
Reference No. E–257–2000/0–US–01);
PCT Application No. PCT/US01/22390
filed 25 Jul 2001 (HHS Reference No.
E–257–2000/0–PCT–02);
U.S. Patent Application No. 10/350,256
filed 21 Jan 2003 (HHS Reference No.
E–257–2000/0–US–03).
Licensing Contact: Peter Soukas; 301/
435–4646; soukasp@mail.nih.gov.
Recently, there has been a renewed
interest in the use of phages to treat
bacterial infections. The inventors have
discovered FK1–5, a highly lytic, nonlysogenic, stable bacteriophage with the
ability to kill bacteria rapidly, making it
a good candidate for phage therapy. The
designation FK1–5 denotes the phage’s
ability to infect E. coli strains that
contain the K1 polysaccharide in their
outer capsule as well as E. coli strains
that contain the K5 polysaccharide in
their outer capsule. Sequence analysis
of the tail proteins of phage FK1–5 by
the inventors has shown that they are
arranged in a cassette structure,
suggesting that the host range of phages
can be broadened to other K antigens,
and even possibly other species of
bacteria by recombinant techniques.
FK1–5 has a particular advantage
because it recognizes and attaches to the
structures that confer virulence to
bacteria. The inventors’ demonstration
that a phage can contain multiple tail
proteins that expand its host range is
useful for generating phage with broadspectrum antibacterial properties for the
treatment of infectious diseases. The
inventors have completed in vitro
studies on this phage. Furthermore,
because of the possibility of engineering
the expression of recombinant tail
proteins, gene transfer to organisms that
are not normally infected by phages is
also contemplated by the invention.
VerDate jul<14>2003
15:22 Aug 02, 2005
Jkt 205001
CC Chemokine Receptor 5 DNA, New
Animal Models and Therapeutic Agents
for HIV Infection
C. Combadiere, Y. Feng, E.A. Berger, G.
Alkahatib, P.M. Murphy, C.C. Broder,
P.E. Kennedy (NIAID).
U.S. Provisional Application No. 60/
018,508 filed 28 May 1996 (HHS
Reference No. E–090–1996/0–US–01);
U.S. Patent Application No. 08/864,458
filed 28 May 1997 (HHS Reference
No. E–090–1996/0–US–04);
U.S. Patent Application No. 10/439,845
filed 15 May 2003 (HHS Reference
No. E–090–1996/0–US–05);
U.S. Patent Application No. 10/700,313
filed 31 Oct 2003 (HHS Reference No.
E–090–1996/0–US–06);
U.S. Patent Application No. 10/846,185
filed 14 May 2004 (HHS Reference
No. E–090–1996/0–US–07);
PCT Application No. PCT/US97/09586
filed 28 May 1997 (HHS Reference
No. E–090–1996/0–PCT–02);
European Patent Application No.
97929777.7 filed 28 May 1997 (HHS
Reference No. E–090–1996/0–EP–03).
Licensing Contact: Peter Soukas; 301/
435–4646; soukasp@mail.nih.gov.
Chemokine receptors are expressed by
many cells, including lymphoid cells,
and function to mediate cell trafficking
and localization. CC chemokine receptor
5 (CCR5) is a seven-transmembrane, G
protein-coupled receptor (GPCR) which
regulates trafficking and effector
functions of memory/effector Tlymphocytes, macrophages, and
immature dendritic cells. Chemokine
binding to CCR5 leads to cellular
activation through pertussis toxinsensitive heterotrimeric G proteins as
well as G protein-independent
signalling pathways. Like many other
GPCR, CCR5 is regulated by agonistdependent processes which involve G
protein coupled receptor kinase (GRK)dependent phosphorylation, betaarrestin-mediated desensitization and
internalization.
Human CCR5 also functions as the
main coreceptor for the fusion and entry
of many strains of human
immunodeficiency virus (HIV–1, HIV–
2). HIV–1 transmission almost
invariably involves such CCR5-specific
variants (designated R5); individuals
lacking functional CCR5 (by virtue of
homozygosity for a defective CCR5
allele) are almost completely resistant to
HIV–1 infection. Specific blocking of
CCR5 (e.g. with chemokine ligands,
anti-CCR5 antibodies, CCR5-blocking
low MW inhibitors, etc.) inhibits entry/
infection of target cells by R5 HIV
strains. Cells expressing CCR5 and CD4
are useful for screening for agents that
inhibit HIV by binding to CCR5. Such
PO 00000
Frm 00115
Fmt 4703
Sfmt 4703
44667
agents represent potential new
approaches to block HIV transmission
and to treat infected people. A small
animal expressing both human CCR5
along with human CD4 supports entry
of HIV into target cells, a necessary
hurdle that must be overcome for
development of a small animal model
(e.g. transgenic mouse, rat, rabbit, mink)
to study HIV infection and its
inhibition.
The invention embodies the CCR5
genetic sequence, cell lines and
transgenic mice, the cells of which
coexpress human CD4 and CCR5, and
which may represent valuable tools for
the study of HIV infection and for
screening anti-HIV agents. The
invention also embodies anti-CCR5
agents that block HIV env-mediated
membrane fusion associated with HIV
entry into human CD4-positive target
cells or between HIV-infected cells and
uninfected human CD4-positive target
cells.
This technology was reported in
Alkhatib et al., ‘‘CC CKR5: a RANTES,
MIP–1alpha, MIP–1beta receptor as a
fusion cofactor for macrophage-tropic
HIV–1,’’ Science 272:1955–1958 (1996).
The technology is available for
exclusive or nonexclusive licensing.
Dated: July 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15347 Filed 8–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
E:\FR\FM\03AUN1.SGM
03AUN1
44668
Federal Register / Vol. 70, No. 148 / Wednesday, August 3, 2005 / Notices
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
A32 Monoclonal Antibody Fusion
Protein for Use as HIV Inhibitors and
Vaccines
Dimiter S. Dimitrov and Mei-yun Zhang
(NCI).
U.S. Provisional Application No. 60/
618,820 filed 14 Oct 2004 (HHS
Reference No. E–302–2004/0–US–01).
Licensing Contact: Sally Hu; 301/435–
5606; hus@mail.nih.gov.
The invention provides composition
claims of a fusion protein, which
comprises an antigen binding portion of
a human antibody called A32 and one
of the following: (a) An antigen-binding
portion of a second antibody that binds
to an epitope of an envelope protein
(i.e., gp120) of a human
immunodeficiency virus (HIV) that is
exposed upon the HIV binding to a CD4
receptor, (b) an immunogenic portion of
an envelope protein of a HIV such as
gp120, or (c) a soluble CD4 (sCD4)
polypeptide capable of binding to HIV.
The invention also provides the method
claims to use the above fusion proteins
as inhibitors of HIV infection and those
containing gp120 such as A32–gp120 as
vaccine immunogens for the treatment
and prevention of HIV. Further
development of the fusion proteins may
yield novel therapies and methods in
the prevention of mother-to-child
transmission of HIV, treatment of
accidental exposure to HIV, and chronic
infection in patients with resistance to
current therapies.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Plasmid and Viral Vectors Expressing a
Microtubule-Directed Fluorescent
Fusion Protein for Cellular Imaging
Dr. Michael J. Iadarola et al. (NIDCR).
HHS Reference No. E–153–1999/0—
Research Tool.
Licensing Contact: Marlene Shinn-Astor;
301/435–4426; shinnm@mail.nih.gov.
This technology is a fluorescent
protein for discrete tracing of intra- and
intercellular connections and for sorting
and isolation of cells. This
recombinantly engineered protein can
be expressed from viral vectors for use
in living animals and in ex vivo
situations involving primary cultured
VerDate jul<14>2003
18:05 Aug 02, 2005
Jkt 205001
cells or from a plasmid for use in cell
lines. The new protein consists of a
fusion between the tau protein, which
binds to microtubules, and enhanced
green fluorescent protein (tau-eGFP).
When cloned into adenovirus, the
contrast can be used for transducing
primary cultures for ex vivo gene
therapy and for use as an anterograde
tracer in brain circuit analysis. These
uses can be a valuable research tool to
help scientists find out how the brain
works, investigate Alzheimer’s disease,
and to identify specific cells for treating
disease via cell transplantation.
Dated: July 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–15348 Filed 8–2–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the meeting of the
President’s Cancer Panel.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(9)(B), title 5 U.S.C., as amended,
because the premature disclosure of
information and the discussions would
likely to significantly frustrate
implementation of recommendations.
Name of Committee: President’s Cancer
Panel.
Date: August 25, 2005.
Open: August 25, 2005, 8 a.m. to 2:30 p.m.
Agenda: Cancer Survivorship: Treatment
Records, Follow-up, and HIPPA.
Place: The Washington Marriott Hotel,
1221 22nd Street, NW., Washington, DC
20037.
Closed: August 25, 2005, 3 p.m. to 5 p.m.
Agenda: The Panel will discuss the
treatment records and follow-up care plans.
Place: The Washington Marriott Hotel,
1221 22nd Street, NW., Washington, DC
20037.
Contact Person: Abby Sandler, Ph.D.,
Executive Secretary, National Cancer
PO 00000
Frm 00116
Fmt 4703
Sfmt 4703
Institute, National Institutes of Health,
Building 6116, Room 212, 6116 Executive
Boulevard, Bethesda, MD 20892. (301) 451–
9399.
Any interested person may file written
comments with the committee by forwarding
the comments to the Contact Person listed on
this notice. The comments should include
the name, address, telephone number and,
when applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s Home page: https://
deainfo.nci.nih.gov/advisory/pcp/pcp.htm,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS).
Dated: July 26, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15243 Filed 8–2–04; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel,
Genetics of Alaska Natives.
Date: August 16, 2005.
Time: 9 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7214, Bethesda, MD
20892. (Telephone conference call.)
E:\FR\FM\03AUN1.SGM
03AUN1
]]>Agencies
[Federal Register Volume 70, Number 148 (Wednesday, August 3, 2005)]
[Notices]
[Pages 44667-44668]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15348]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the
[[Page 44668]]
Office of Technology Transfer, National Institutes of Health, 6011
Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804;
telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential
Disclosure Agreement will be required to receive copies of the patent
applications.
A32 Monoclonal Antibody Fusion Protein for Use as HIV Inhibitors and
Vaccines
Dimiter S. Dimitrov and Mei-yun Zhang (NCI).
U.S. Provisional Application No. 60/618,820 filed 14 Oct 2004 (HHS
Reference No. E-302-2004/0-US-01).
Licensing Contact: Sally Hu; 301/435-5606; hus@mail.nih.gov.
The invention provides composition claims of a fusion protein,
which comprises an antigen binding portion of a human antibody called
A32 and one of the following: (a) An antigen-binding portion of a
second antibody that binds to an epitope of an envelope protein (i.e.,
gp120) of a human immunodeficiency virus (HIV) that is exposed upon the
HIV binding to a CD4 receptor, (b) an immunogenic portion of an
envelope protein of a HIV such as gp120, or (c) a soluble CD4 (sCD4)
polypeptide capable of binding to HIV. The invention also provides the
method claims to use the above fusion proteins as inhibitors of HIV
infection and those containing gp120 such as A32-gp120 as vaccine
immunogens for the treatment and prevention of HIV. Further development
of the fusion proteins may yield novel therapies and methods in the
prevention of mother-to-child transmission of HIV, treatment of
accidental exposure to HIV, and chronic infection in patients with
resistance to current therapies.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Plasmid and Viral Vectors Expressing a Microtubule-Directed Fluorescent
Fusion Protein for Cellular Imaging
Dr. Michael J. Iadarola et al. (NIDCR).
HHS Reference No. E-153-1999/0--Research Tool.
Licensing Contact: Marlene Shinn-Astor; 301/435-4426;
shinnm@mail.nih.gov.
This technology is a fluorescent protein for discrete tracing of
intra- and intercellular connections and for sorting and isolation of
cells. This recombinantly engineered protein can be expressed from
viral vectors for use in living animals and in ex vivo situations
involving primary cultured cells or from a plasmid for use in cell
lines. The new protein consists of a fusion between the tau protein,
which binds to microtubules, and enhanced green fluorescent protein
(tau-eGFP). When cloned into adenovirus, the contrast can be used for
transducing primary cultures for ex vivo gene therapy and for use as an
anterograde tracer in brain circuit analysis. These uses can be a
valuable research tool to help scientists find out how the brain works,
investigate Alzheimer's disease, and to identify specific cells for
treating disease via cell transplantation.
Dated: July 19, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-15348 Filed 8-2-05; 8:45 am]
BILLING CODE 4140-01-P
